Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Evarucabgene Autoleucel · NXC-201, HBI0101

Cell therapy (CAR-T) · Kills target cells, directed at BCMA (TNFRSF17) · developed by Nexcella

Phase 3 Most advanced trial

2 Registered trials

What is Evarucabgene Autoleucel?

Evarucabgene autoleucel is an autologous CAR-T cell therapy engineered to express a chimeric antigen receptor targeting BCMA (TNFRSF17), a tumor-associated antigen overexpressed on malignant plasma cells. The CAR includes a 4-1BB co-stimulatory domain. It is being studied in light chain amyloidosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: NXC-201, HBI0101
Drug type: Cell therapy (CAR-T)
Targets: BCMA (TNFRSF17) (antigen)
Mechanism: Kills target cells, directed at BCMA (TNFRSF17)
Pathways: immunostimulation, cytotoxicity
Therapy area: Metabolic, Oncology
Developer: Nexcella Inc.
In trials of: IMMX
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 2276KMR6L5

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07709715	Phase 3	Light Chain (AL) Amyloidosis	Not yet recruiting	IMMX
NCT06097832	Phase 1/2	Light Chain (AL) Amyloidosis	Active not recruiting	IMMX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Light Chain (AL) Amyloidosis

Other drugs acting on TNFRSF17

SEA-BCMA Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z